Polymeric and lipidic nanoparticles in transforming anti-HIV combinational therapy: can they turn the tide?

Abstract

The HIV-1 pandemic presents a multifaceted challenge across the globe, standing as the foremost public health crisis today. Global data on HIV-related morbidity and mortality are alarming. Effective HIV management hinges on minimizing transmission through highly active antiretroviral therapy (HAART), which relies on a combination of HAART and has been a cornerstone in HIV management. However, challenges such as low patient adherence, suboptimal drug pharmacokinetics, and side effects, potentially undermine the efficacy of existing treatment. Emerging nanotherapeutics, particularly lipidic and polymeric nanoparticles, have exhibited immense promise in addressing these concerns. These nanocarriers enhance targeted drug delivery, facilitate controlled release, and reduce toxicity. Notably, co-delivery strategies using nanoparticles enable the simultaneous transport of multiple drugs involved in HAART. But the question arises whether the exploration is enough to turn the tide. Hence, through this review, the authors have tried to explore and discuss the obstacles faced by the lipid and polymeric nanoparticles such as stability and encapsulation efficiency, and translating these innovations to clinical practice in detail and discussed the future potential of AI-driven nanomedicine.

Keywords: Co-delivery; Highly active antiretroviral therapy; Human immunodeficiency virus; Nanoparticles; Targeted delivery.